Anti-hMENA11a Antibody, clone A1

Protein enabled homolog (UniProt: A0A097PIC4; also known as hMENA, Mammalian enabled variant 11a, ENAH) is encoded by the ENAH (also known as MENA) gene (Gene ID: 55740) in human. hMENA is a homotetrameric actin regulatory protein of the ENA/VASP family that plays a key role in cell processes that rely on actin cytoskeleton dynamics. Its expression is observed in a variety of tissues. It is overexpressed in a majority of breast cancer cell lines and primary breast tumor lesions. Its EVH2 domain mediates tetramerization, F-actin binding, and actin bundle formation. The EVH2 domain is comprised of three regions: Block A (aa 391-411) is a thymosin-like domain that is essential for G-actin binding; block B (aa 442-459) is required for F-actin binding and subcellular location, and block C (aa 554-588) is required for tetramerization. It also contains a KLKR motif (aa 400-403) within block A that is reported to be essential for G-actin binding and actin polymerization. hMENA is absent in normal breast tissue, but it is overexpressed in breast tumors, where its expression correlates with HER-2-positive, ER-negative, and high Ki 67 phenotype. Depletion of hMENA/ hMENA11 is reported to decrease HER3 phosphorylation, inhibits EGF- and NRG-mediated activation of EGFR and HER-2 and counteract growth factor-mediated cell proliferation. Silencing of hMENA/hMENA11a is reported to switch on molecules linked to apoptosis, including cleaved forms of poly (ADP-ribose) polymerase and caspase 9. A hMENA v6 variant of hMENA has also been described that increases cell invasion. In an isogenic model of human breast cancer progression, hMENA11a expression is observed in premalignant cells, whereas hMENA v6 expression is restricted to invasive cancer cells. (Ref.: Melchionna, R., et al. (2020). EMBO Rep. 21; e50078; Trono, P., et al. (2016). Mol. Cell. Oncol. 3(2); e1083648; Di Modugnoa, F., et al. (2012). Proc. Natl. Acad. Sci. USA. 109(47); 19280-19285).

A linear peptide corresponding to 18 amino acids from the C-terminal region of human MENA protein belonging to 11a exon.

Quality Control Testing

Evaluated by Western Blotting in T47D cell lysate.

Western Blotting Analysis: A 1:500 dilution of this antibody detected hMENA11a in T47D cell lysate.

Tested Applications

Immunocytochemistry Analysis: A representative lot detected MENA11a/ENAH in Western Blotting application (Di Modugno, F., et al. (2012). Proc Natl Acad Sci USA. 109(47):19280-5; Melchionna, R., et al. (2020). EMBO Rep. 21(11):e50078).

Western Blotting Analysis: A representative lot detected MENA11a/ENAH in Western Blotting applications (Di Modugno, F., et al. (2012). Proc Natl Acad Sci USA. 109(47):19280-5).

Immunohistochemistry Applications: A representative lot detected MENA11a/ENAH in Immunohistochemistry applications (Di Modugno, F., et al. (2012). Proc Natl Acad Sci USA. 109(47):19280-5).

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Clone A1 is a mouse monoclonal antibody that detects hMENA 11a. It targets an epitope within 18 amino acids from the C-terminal region.

Purified mouse monoclonal antibody IgG1 in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

0.5 mg/mL. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommended storage: +2°C to +8°C.

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.